Allergan appoints Adriane M. Brown to board of directors
pharmafile | November 14, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allergan
Allergan announced that Adriana M. Brown will join its board of directors on February 2017. Adriana Brown is currently the president and chief operating officer of Intellectual Ventures, a private global invention company that focuses on providing access to valuable patents and invention related services.
Adriana Brown’s experience prior to joining Allergan’s board of directors includes working at Intellectual Ventures from 2010; she performed the role of senior vice president of Energy Strategy at Honeywell international, where she worked for eleven years within numerous roles.
“I am pleased to join the board of Allergan as they deliver results around the world that serve their customers and patients,” said Brown, commenting on her appointment. “Their commitment to innovative and meaningful work with the goal of helping people live longer and healthier is commendable.”
“Adriane Brown is an accomplished executive with extensive experience leading global businesses in multiple industries. With nearly 30 years of management experience, she has operational know how and a proven track record of developing and growing technologies and products across a network of global R&D centers and manufacturing plants,” said Brent Saunders, chairman, chief executive officer and president of Allergan. “Adriane’s public board experience, understanding of the value of innovation and experience developing and protecting intellectual property complements the experiences of our current board.”
Related Content
FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
New Phase 3 data has been released showing that both 50mg and 100mg doses of …
